Back to School: How biopharma can reboot drug development. Access exclusive analysis here
SkyePharma (LSE:SKP; SKYE) will use its Geomatrix oral drug
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury